Abstract | Objective: Methods: Clinical data of 92 patients with advanced squamous cell carcinoma of the lung treated with erlotinib and TS-1 in our hospital (January 2017-January 2021) were retrospectively analyzed. Forty-six patients receiving conventional nursing were set as the control group (CG), and other 46 patients receiving evidence-based nursing intervention additionally were set as the study group (SG). The clinical observation indexes of the two groups were compared and analyzed. Results: No obvious difference in general data between both groups (P > 0.05). According to EORTC QLQ-C30, compared with the CG, the scores of role function, physical function, social function, cognitive function, and emotional function in the SG were remarkably higher (P < 0.05). After intervention, scores of VAS of patients were obviously lower than those before intervention (P < 0.05), and scores of VAS in the SG after intervention were obviously lower than those in the CG (P < 0.05). After intervention, scores of SAS and SDS were lower than those before intervention, and those of the SG were obviously lower than those of the SG (P < 0.05). Compared with the CG, incidences of adverse reactions such as diarrhoea, nausea and vomiting, erythra, pressure sores, and leukopenia in the SG were obviously lower (P < 0.05). Compared with the CG, "very satisfied" and total satisfaction in the SG were obviously higher (P < 0.05). Conclusion: Application of evidence-based nursing intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib combined with TS-1 can help patients to relieve pain, improve their psychological state, reduce the incidence of adverse reactions, significantly improve the QOL, and also enhance the satisfaction of clinical nursing.
|
Authors | Shan Liu, Xiaocheng Huang, Jin Wen, Fangfang Fu, Huifen Wang |
Journal | Journal of healthcare engineering
(J Healthc Eng)
Vol. 2021
Pg. 6801779
( 2021)
ISSN: 2040-2309 [Electronic] England |
PMID | 34938422
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Shan Liu et al. |
Chemical References |
- Pyridines
- Tegafur
- Oxonic Acid
- Erlotinib Hydrochloride
- Potassium
- gimeracil
|
Topics |
- Carcinoma, Squamous Cell
(chemically induced, drug therapy)
- Erlotinib Hydrochloride
- Evidence-Based Nursing
- Humans
- Lung
- Oxonic Acid
(adverse effects)
- Potassium
- Pyridines
- Quality of Life
- Retrospective Studies
- Tegafur
(adverse effects)
|